Novacyt (NCYT) Competitors

Novacyt (LON:NCYT) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Does the media refer more to NCYT or EKF?

In the previous week, EKF Diagnostics had 1 more articles in the media than Novacyt. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Novacyt. EKF Diagnostics' average media sentiment score of 1.05 beat Novacyt's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Novacyt	Neutral
EKF Diagnostics	Positive

Which has higher earnings and valuation, NCYT or EKF?

EKF Diagnostics has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novacyt	£18.56M	1.90	-£37.36M	-£0.52	-96.15
EKF Diagnostics	£50.95M	2.30	£4.78M	£0.01	2,580.00

Which has more volatility & risk, NCYT or EKF?

Novacyt has a beta of -1.86, indicating that its stock price is 286% less volatile than the S&P 500. Comparatively, EKF Diagnostics has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.

Is NCYT or EKF more profitable?

EKF Diagnostics has a net margin of 9.37% compared to Novacyt's net margin of -202.80%. EKF Diagnostics' return on equity of 7.58% beat Novacyt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novacyt	-202.80%	-42.04%	-27.98%
EKF Diagnostics	9.37%	7.58%	5.27%

Do insiders and institutionals hold more shares of NCYT or EKF?

0.1% of Novacyt shares are held by institutional investors. Comparatively, 70.3% of EKF Diagnostics shares are held by institutional investors. 3.1% of Novacyt shares are held by insiders. Comparatively, 5.2% of EKF Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the MarketBeat Community prefer NCYT or EKF?

EKF Diagnostics received 291 more outperform votes than Novacyt when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 58.06% of users gave Novacyt an outperform vote.

Company	Underperform	Outperform
Novacyt	Outperform Votes 36 58.06%	Underperform Votes 26 41.94%
EKF Diagnostics	Outperform Votes 327 76.76%	Underperform Votes 99 23.24%

Summary

EKF Diagnostics beats Novacyt on 15 of the 15 factors compared between the two stocks.